Keywords: gsk, arixtra, comparable, sanofi-aventis, lovenox, trials, data
GSK's Arixtra comparable to Sanofi-Aventis's Lovenox in trials
Article | 17 April 2006
Data published in the New England Journal of Medicine show that UK drug major GlaxoSmithKline's antithrombotic agent Arixtra (fondaparinux sodium) ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- US Supreme Court says patent settlement can "sometimes" be illegal
- Actavis and Kissei file law suits against Sandoz and Hetero over Rapaflo patent
